Unda
ActiveSummary
Unda has been active since 1951 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €486,787 and a net result of €61,912. Equity is growing by ~7.3% per year across the filed fiscal years. Its solvency ranks better than 93% of 68 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability67▲+45
Solvency100=
Growth38=
Track record100
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40,000 at 30 days acceptable
Liquidity ample (current ratio 13.68 against 9.72 in 2024; short-term debt: 6% of total assets), and 6% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
94%
Return on assets
12%
Age of the figures
9 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-06-2026, 51 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
51 d early
2024
37 d early
2023
48 d early
2022
35 d early
2021
13 d early
2020
15 d early
2019
15 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 31 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 24 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
29-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
Turnover
€102,715▼ 97.9%
2019 · €4.9m
EBIT margin
-9.0%▲ 103.6pp
2019 · -112.5%
Net result
€61,912
2024 · -€28,705
Working capital
€390,715▼ 6.8%
2024 · €419,365
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Turnover
Operating result€5,730-€62,404€171,296-€44,814€53,928
Net result€3,289within the sector's middle half-€61,225within the sector's middle half€186,161within the sector's middle half-€28,705within the sector's middle half€61,912within the sector's middle half
EBIT margin
Equity€328,644below the sector's middle half▲ 1.0%€267,420below the sector's middle half▼ 18.6%€453,581below the sector's middle half▲ 69.6%€424,875below the sector's middle half▼ 6.3%€486,787within the sector's middle half▲ 14.6%
Total assets€1.1mbelow the sector's middle half▼ 34.8%€575,985below the sector's middle half▼ 46.3%€481,814below the sector's middle half▼ 16.3%€473,026below the sector's middle half▼ 1.8%€517,605below the sector's middle half▲ 9.4%
Debt€142,203▼ 12.7%€51,722▼ 63.6%€28,233▼ 45.4%€48,150▲ 70.5%€30,818▼ 36.0%
Working capital€924,227within the sector's middle half▼ 37.4%€518,111within the sector's middle half▼ 43.9%€448,018within the sector's middle half▼ 13.5%€419,365within the sector's middle half▼ 6.4%€390,715within the sector's middle half▼ 6.8%
Solvency30.6%within the sector's middle half▲ 10.9pp46.4%within the sector's middle half▲ 15.8pp94.1%above the sector's middle half▲ 47.7pp89.8%above the sector's middle half▼ 4.3pp94.0%above the sector's middle half▲ 4.2pp
Current ratio7.50above the sector's middle half▼ 2.5611.02above the sector's middle half▲ 3.5216.87above the sector's middle half▲ 5.859.72above the sector's middle half▼ 7.1513.68above the sector's middle half▲ 3.96
Return on assets (ROA)0.3%within the sector's middle half▲ 1.5pp-10.6%below the sector's middle half▼ 10.9pp38.6%above the sector's middle half▲ 49.3pp-6.1%within the sector's middle half▼ 44.7pp12.0%above the sector's middle half▲ 18.0pp
Staff (FTE)1.1below the sector's middle half▼ 45.0%1below the sector's middle half▼ 9.1%0.5below the sector's middle half▼ 50.0%0below the sector's middle half▼ 100%0below the sector's middle half
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Result per fiscal year
Operating resultNet result
The operating result returns to profit in 2025: €53,928 after a loss of €44,814 in 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €517,605
Fixed assets
€96,072 ▲ 1,627%
Current assets
€421,533 ▼ 9.8%
Equity and liabilities €517,605
Equity
€486,787 ▲ 14.6%
Debt
€30,818 ▼ 36.0%
Debt's share of the balance-sheet total falls from 10.2% to 6.0%. Equity is higher and debt is lower.
Key figures and ratios
Debt to equity
0.06▼
2024 · 0.11
ROE
12.7%▲
2024 · -6.8%
Debt ≤ 1 year
€30,818▼
2024 · €48,097
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 20,134 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 95% are still going.
- Small
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.2%
went bankrupt
4.7%
stopped otherwise
95%
still going
For this company itself Checked computes a bankruptcy probability of 0.2% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,338 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.9% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 20,134 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | €90,509 | - |
| Goods, raw materials, services and sundry goods60/61 | €370,519 | - | - | - | - | - |
| Remuneration, social security and pensions62 | €182,768 | €62,996 | €12,956 | €0 | - | - |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | €8,313 | €0 | - | - | - |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | -€556,216 | -€344,892 | -€256,843 | €0 | - | - |
| Other operating charges640/8 | €912 | €3,004 | €4,508 | €528 | €0 | ▼ 100% |
| Gross operating margin9900 | -€366,804 | -€332,983 | -€68,082 | -€44,286 | €53,928 | ▲ 222% |
| Operating profit (loss)9901 | €5,730 | -€62,404 | €171,296 | -€44,814 | €53,928 | ▲ 220% |
| Financial income75/76B | - | €2,369 | €15,971 | €16,968 | €9,234 | ▼ 45.6% |
| Recurring financial income75 | - | €2,369 | €15,971 | €16,968 | €9,234 | ▼ 45.6% |
| Non-recurring financial income76B | - | - | - | - | €0 | - |
| Financial charges65/66B | €1,872 | €1,189 | €1,106 | €859 | €1,251 | ▲ 45.6% |
| Recurring financial charges65 | €1,872 | €1,189 | €1,106 | €859 | €1,251 | ▲ 45.6% |
| Profit (loss) for the period before taxes9903 | €3,858 | -€61,225 | €186,161 | -€28,705 | €61,912 | ▲ 316% |
| Income taxes67/77 | €569 | €0 | €0 | - | - | - |
| Profit (loss) for the period9904 | €3,289 | -€61,225 | €186,161 | -€28,705 | €61,912 | ▲ 316% |
| Transfer from tax-exempt reserves789 | - | €0 | - | - | - | - |
| Transfer to tax-exempt reserves689 | - | €0 | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €3,289 | -€61,225 | €186,161 | -€28,705 | €61,912 | ▲ 316% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €1.1m | €575,985 | €481,814 | €473,026 | €517,605 | ▲ 9.4% |
| Formation expenses20 | - | €0 | - | - | - | - |
| Fixed assets21/28 | €6,152 | €6,152 | €5,563 | €5,563 | €96,072 | ▲ 1,627% |
| Intangible fixed assets21 | - | €0 | - | - | - | - |
| Financial fixed assets28 | €6,152 | €6,152 | €5,563 | €5,563 | €96,072 | ▲ 1,627% |
| Current assets29/58 | €1.1m | €569,833 | €476,251 | €467,463 | €421,533 | ▼ 9.8% |
| Amounts receivable within one year40/41 | €1.1m | €568,043 | €476,219 | €467,463 | €421,533 | ▼ 9.8% |
| Trade receivables40 | €17,255 | €2,695 | €2,695 | €6,053 | €2,695 | ▼ 55.5% |
| Other amounts receivable41 | €1.0m | €565,348 | €473,523 | €461,410 | €418,837 | ▼ 9.2% |
| Cash at bank and in hand54/58 | €840 | €840 | €0 | - | - | - |
| Deferred charges and accrued income490/1 | €37 | €950 | €33 | - | - | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €1.1m | €575,985 | €481,814 | €473,026 | €517,605 | ▲ 9.4% |
| Equity10/15 | €328,644 | €267,420 | €453,581 | €424,875 | €486,787 | ▲ 14.6% |
| Contributions10/11 | €61,500 | €61,500 | €61,500 | €61,500 | €61,500 | = |
| Capital10 | €61,500 | €61,500 | €61,500 | €61,500 | €61,500 | = |
| Issued capital100 | €61,500 | €61,500 | €61,500 | €61,500 | €61,500 | = |
| Reserves13 | €560,391 | €560,391 | €560,391 | €560,391 | €560,391 | = |
| Non-distributable reserves130/1 | €7,354 | €7,354 | €7,354 | €7,354 | €7,354 | = |
| Legal reserve130 | €6,150 | €6,150 | €6,150 | €6,150 | €6,150 | = |
| Other1319 | €1,204 | €1,204 | €1,204 | €1,204 | €1,204 | = |
| Tax-exempt reserves132 | €109,413 | €109,413 | €109,413 | €109,413 | €109,414 | = |
| Distributable reserves133 | €443,624 | €443,624 | €443,624 | €443,624 | €443,624 | = |
| Profit (loss) carried forward14 | -€293,247 | -€354,471 | -€168,310 | -€197,016 | -€135,104 | ▲ 31.4% |
| Provisions and deferred taxes16 | €601,735 | €256,843 | €0 | - | - | - |
| Provisions for liabilities and charges160/5 | €601,735 | €256,843 | €0 | - | - | - |
| Other liabilities and charges164/5 | €601,735 | €256,843 | €0 | - | - | - |
| Amounts payable17/49 | €142,203 | €51,722 | €28,233 | €48,150 | €30,818 | ▼ 36.0% |
| Amounts payable within one year42/48 | €142,203 | €51,722 | €28,233 | €48,097 | €30,818 | ▼ 35.9% |
| Trade debts44 | €119,485 | €31,129 | €11,643 | €31,507 | €14,529 | ▼ 53.9% |
| Suppliers440/4 | €119,485 | €31,129 | €11,643 | €31,507 | €14,529 | ▼ 53.9% |
| Taxes, remuneration and social security45 | €6,429 | €4,305 | €302 | €302 | €0 | ▼ 100% |
| Taxes450/3 | €1,571 | €1,649 | €84 | €84 | €0 | ▼ 100% |
| Remuneration and social security454/9 | €4,858 | €2,655 | €218 | €218 | - | - |
| Other amounts payable47/48 | €16,289 | €16,289 | €16,289 | €16,289 | €16,289 | = |
| Accrued charges and deferred income492/3 | - | €0 | - | €53 | €0 | ▼ 100% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €3,289 | -€61,225 | €186,161 | -€28,705 | €61,912 | ▲ 316% |
| Operating cash flow (approximation) | €3,289 | -€61,225 | €186,161 | -€28,705 | €61,912 | ▲ 316% |
| Investment in fixed assets (approximation) | - | €0 | €589 | €0 | -€90,509 | - |
| Change in cash | - | €0 | -€840 | - | - | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
10-06
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Back to profitnet €61,912
Net result €61,912 after one loss-making year.
24-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
13-06
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Back to profitnet €186,161
Net result €186,161 after one loss-making year.
26-06
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
18-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
31-12
Financial
Back to profitnet €3,289
Net result €3,289 after 3 loss-making years.
16-07
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
31-12
Financial
Liquidity times 27current ratio 10.06
Current ratio from 0.38 to 10.06; short-term debt falls from €3.7m to €162,975.
31-12
Financial
Equity above €200,000Eq €325,355
Equity rises from -€3.9m to €325,355.
16-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
Show earlier events
2019
31-12
Financial
Weakest financial yearnet -€5.6m
Net result drops to -€5.6m, the lowest in the series; recovery starts the following year.
08-08
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 8 days late
2018
13-06
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
31-05
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 30 acts read
About the unread acts
We know of 30 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
30 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Aywaille · 1 establishment unit since 2003
Ground area
2.3 ha
Building footprint
3,451 m²
Volume, LiDAR
20,962 m³
Parcel 61026A1009/00K003, Wallonia · tallest building 8.6 m, ±2 floors. Linked by address, not a title deed.
2
companies at this address
See who is registered here
1 establishment unit
Unda
since 20032.133.023.763
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 61026A1009/00K003 | Wallonia | 2.3 ha | 1 · 3,451 m² | 8.6 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Owners and holdings
7 ownersChain of control
- BOIRON SAFR
- Unda
Highest known parent: BOIRON SA (France). The sources do not say who stands above it.
Owners 7
- BOIRON SAFRparentSourceown accounts 202599.99%
- Paul Moreaunatural personSourceown accounts 20250.01%
-
0%
- Dominique Teteaunatural personSourceown accounts 20250%
- Jan Moskalanatural personSourceown accounts 20250%
- Jeanine Teteaunatural personSourceown accounts 20250%
- Micheline Osterwindnatural personSourceown accounts 20250%
Holdings 0
The accounts to 31-12-2025 list no holdings, and no other source names one.
According to the 2025 annual accounts of Unda and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Similar companies · same sector, comparable size
Groovy.Bio
BE 0776.937.633
Antwerpen · Eq €544,484
Pharmacie de Vesnau
BE 0894.776.696
Ittre · Eq €414,399
SOFIA COSMETICA
BE 0428.575.692
Herk-de-Stad · Eq €577,957
PANNOC CHEMIE
BE 0418.262.812
Olen · Eq €409,659
OLYS Pharma
BE 0754.895.372
La Hulpe · Eq €578,974
Of 148 companies in sector 21201 we hold annual accounts for 118. 56 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded17-10-1951
Fiscal year end31-12
Abbreviation FR
U.H.
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
E-invoicing
Reachable via Peppol
Peppol ID
0208:0403987182
Registered
05-12-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 29 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.